Collagenase - Biologic Drug Details

Summary for collagenase

Tradenames:	1
High Confidence Patents:	3
Applicants:	3
BLAs:	3
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for collagenase

Recent Clinical Trials for collagenase

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National University Hospital, Singapore	PHASE2
National Medical Research Council (NMRC), Singapore	PHASE2
MediWound Ltd	PHASE2

See all collagenase clinical trials

Pharmacology for collagenase

Ingredient-type	Collagenases
Established Pharmacologic Class	Collagen-specific Enzyme

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for collagenase Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for collagenase Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2036-09-09	DrugPatentWatch analysis and company disclosures
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2034-04-17	DrugPatentWatch analysis and company disclosures
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2035-11-23	DrugPatentWatch analysis and company disclosures
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2036-12-01	DrugPatentWatch analysis and company disclosures
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2035-01-08	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for collagenase Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995		2033-11-11	Patent claims search
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995		2035-12-21	Patent claims search
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995		2036-11-03	Patent claims search
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995		2032-10-01	Patent claims search
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995		2031-06-06	Patent claims search

Collagenase Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics of Collagenase?

The collagenase market is driven by its demand in medical procedures, particularly in the treatment of Dupuytren's contracture, Peyronie's disease, and certain wound management applications. Variability exists based on geographic adoption, regulatory approvals, and clinical guidelines.

Market Size and Growth

In 2022, the global collagenase market was valued at approximately $600 million. It is projected to reach around $900 million by 2027, with a compound annual growth rate (CAGR) of 8% (L.E.K. Consulting, 2022). The growth is primarily fueled by increasing cases of connective tissue disorders, rising aging population, and expanding use of minimally invasive procedures.

Key Drivers

• Clinical Adoption: Collagenase's FDA approval for Dupuytren's contracture in 2010 catalyzed market growth. The minimally invasive nature and outpatient procedure setup favor increasing adoption.
• Research Expansion: Recent studies explore additional indications such as frozen shoulder and adhesive capsulitis, expanding potential markets.
• Regulatory Landscape: Approval in European countries and emerging markets supports regional growth. Some regions still lack approval, limiting access.

Competitive Landscape

Major players include:

• Asklepios BioPharmaceutical (AbbVie): Market leader with broad distribution channels.
• Mediphysis and Roche: Focused on niche indications and developing biosimilar collagenases.
• Innovator Strategies: Developing next-generation formulations aimed at improved tissue specificity and reduced immunogenicity.

Regional Variations

North America dominates the market, accounting for approximately 60% of sales in 2022. Europe contributes around 25%, with growth driven by increased regulatory approvals. Asia-Pacific accounts for roughly 10%, with rapid adoption in China and India but limited by regulatory hurdles.

Market Constraints

• Pricing and Reimbursement: Cost varies; insurance coverage influences adoption.
• Manufacturing Challenges: Production complexity related to enzyme sourcing and stability.
• Alternative Treatments: Emergence of surgical options or other minimally invasive therapies can limit collagenase penetration.

What Is the Financial Trajectory for Collagenase?

Financial performance hinges on sales volumes, pricing strategies, research investments, and patent expirations.

Revenue Trends

Revenue growth is steady but shows signs of plateauing in mature markets as penetration approaches saturation. The $600 million valuation in 2022 reflects consistent quarterly sales increases, estimated at 7–10% annually.

Pricing Dynamics

• Pricing per treatment: Ranges from $3,000 to $4,500 per injection, depending on region.
• Reimbursement: Insurance coverage in North America supports price stability; regions with limited reimbursement see reduced sales.

R&D and Innovation

Annual R&D budgets are approximately 15% of sales. Ongoing research aims to:

• Enhance enzyme stability for extended shelf-life.
• Develop indications for additional connective tissue disorders.
• Reduce immunogenicity and adverse reactions.

Patent Expirations and Market Entry

Key patents on collagenase formulations expire between 2025 and 2028, opening the market to biosimilar entrants. Biosimilars could reduce treatment costs by 20–40%, pressuring incumbent pricing models.

Investment Outlook

• Short-term: Expect moderate growth driven by existing indications and geographic expansion.
• Medium-term: Biosimilar competition may impact sales volumes and margins.
• Long-term: Diversification into new indications and formulations could stabilize revenue streams.

What Are the Key Considerations for Stakeholders?

• Regulatory pathways influence market access timelines.
• Pricing and reimbursement policies directly impact adoption rates.
• Patent losses open opportunities but also mirror increased competition.
• Innovation pipeline success determines the extension of product lifecycle.

Key Takeaways

• The collagenase market is growing at approximately 8% CAGR, driven by its application in connective tissue disorders.
• North America dominates sales, with Europe and emerging markets representing growth avenues.
• Major companies invest around 15% of sales into R&D to develop next-generation formulations.
• Patent expirations from 2025 onward are likely to introduce biosimilar competition, impacting pricing.
• Expanding indications and formulations will be essential for sustained revenue growth.

FAQs

1. What are the main medical indications for collagenase?
Dupuytren's contracture, Peyronie's disease, and select wound debridement procedures.

2. How does biosimilar entry affect collagenase's market?
It is expected to reduce treatment costs and pressure revenue through increased competition post-patent expiration.

3. What regions show the highest growth potential?
Asia-Pacific, due to increasing healthcare infrastructure and unmet demand, and Europe through expanded approval and reimbursement.

4. Are there any significant risks for collagenase market players?
Yes. Patent expiry, emerging competitors, and regulatory delays can hinder growth.

5. What future innovations are anticipated?
Longer shelf-life formulations, broader indications, and reduced immunogenicity.

---

Citations:

[1] L.E.K. Consulting, 2022. "Global Collagenase Market Report."